As nationwide Covid-19 vaccination drive begins, Serum Institute of India (SII) CEO Adar Poonawalla on Saturday received Covid-19 vaccine - Covidshield in Pune.
A SpiceJet flight carrying the vaccines left for the national capital around 8 am, three hours after three trucks with the maiden consignment of the vaccines rolled out of the Serum Institute of India facility, 15 km from the airport.
Three temperature-controlled trucks rolled out of the Serum Institute gates shortly before 5 am and left for Pune airport, from where the vaccines will be flown across India.
Pune-based vaccine major Serum Institute of India (SII) on Monday said it has received an order from the government for as many as 11 million vaccine doses of Covishield, ahead of the January 16 mega vaccination drive.
The Central government on Saturday said India will launch its COVID-19 vaccination drive from January 16, with priority to be given to nearly three crore health care and frontline workers.
Is your skincare routine essentially complete by simply using a cleanser, toner, moisturizer? In order to achieve that smooth and glossy skin one must begin with serums. Serums are the pinnacle of gold captured in a small bottle for the eternal youthful skin.
The Serum Institute of India and Bharat Biotech have jointly communicate their pledge towards a smooth roll out of COVID-19 vaccines to India and the world.
Coronavirus vaccine developed by AstraZeneca and the University of Oxford will cost USD 3-4 per shot (Rs 219-292) to the government and will be priced at double that rate in private market ones such sales open up, said the CEO of its Indian manufacturer on Monday.
Drugs Controller General of India grants permission to Serum Institute of India to manufacture its COVID-19 vaccine ‘Covishield’. The Pune-based company earlier stated that ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield, while Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla on Sunday assured that the Covishield vaccine, which has received approval for restricted emergency use, is "very safe".
As India gears up for the world's largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the COVID-19 vaccines regarding impotency, rubbishing such speculations as "absolute nonsense".
Poonawalla'' remarks came soon after after India's drugs regulator, Drug Controller General of India (DCGI) approved Covishield for restricted emergency use.
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
Samajwadi Party president Akhilesh Yadav Saturday termed the COVID-19 vaccines to be rolled out in the country as "vaccine of the BJP" and said he would not take the shot, drawing a sharp retort from the ruling party which accused him of "insulting" the doctors and scientists.
The analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee and their next meeting will be held on January 1.
Serum Institute of India's application for emergency use authorisation will be considered by the expert panel today. This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use.
The Serum Institute of India (SII) has submitted additional data required by the Drug Controller General of India (DCGI) for determining the safety and immunogenicity of its Covid-19 vaccine candidate, Covishield, sources privy to the development told IANS.
Serum Institute of India said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year
The applications of Bharat Biotech, Serum Institute and Pfizer seeking emergency use authorisation for their COVID-19 vaccines are being examined, the Centre said on Tuesday asserting that drug regulator DCGI seeking more data from these companies will not impact the vaccine-roll out timeline.
Top News
Latest News
